(1 - 18 from 24
)
Panel to Review Vivus Anti-Obesity Drug
online.wsj.com
[Wall Street Journal] - Chief Executive Leland Wilson said the July 15 review will mark a critical milestone for Qnexa and the company. Vivus is one of three drug developers hoping
RxNews Recap for Friday
www.biomedreports.com
[BioMedReports (subscription) (blog)] - The target date for the FDA to complete its review of the Qnexa NDA is October 28, said Leland Wilson, chief executive officer of VIVUS.
VIVUS Inc. (VVUS) President & - GuruFocus.com
www.gurufocus.com
President & CEO of VIVUS Inc. (VVUS) Leland F Wilson sells 200,000 shares of VVUS on at an average price of $ a share.
Qnexa Diet Pill!
news.lalate.com
by lalate Leland Wilson, president and chief executive officer of VIVUS said of the results: “The outstanding results from the EQUIP and CONQUER studies, in addition to the results from EQUATE that were reported late last year, ...
sorted by relevance / date